[1]魏艳胜,王中明,张素清. 替罗非班对急性冠脉综合征择期PCI术临床预后的影响[J]. 中国实用医药, 2012,7(10):8-10. [2]张学强. 不同剂量替罗非班联合冠脉介入治疗非ST段抬高型急性冠脉综合征患者的临床疗效[J]. 中国老年学杂志, 2016,36(7):1613-1615. [3]Pu J, Ding S, He B. Ｒebuttal: TIMI myocardial perfusion frame count: an angiographic method to assess flow in the myocardium but not in the epicardial artery[J]. Catheter Cardiovasc Interv, 2010,76(4):1073-1075. [4]张奇,张瑞岩,胡健,等. 急性ST段抬高心肌梗死患者急诊介入治疗单纯冠状动脉内注射替罗非班的疗效及安全性[J]. 中国介入心脏病学杂志,2014,22(8):483-487. [5]Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions,the task force for percutancous coronary interventions of the european society of cardiology[J]. Eur Heart J, 2005,26(8):804-847. [6]吴惠珍, 李静, 吕迁洲. 血小板Ⅱb/Ⅲa受体拮抗药盐酸替罗非班临床研究现状[J]. 中国药房, 2008,19(8):627-630. [7]段素萍,刘剑,赵桂娥,等. 不同剂量阿司匹林干预对非ST段抬高性急性冠脉综合征患者机体炎症水平及血管内皮功能的影响[J]. 现代生物医学进展, 2012,12(13):2545-2548. [8]张肃, 姚斌. 替罗非班治疗围介入术期高危非ST段抬高型急性冠脉综合征的效果研究[J]. 中国生化药物杂志, 2014,3(34):105-107. [9]赵倡武, 苏毅, 马欣. 替罗非班对急性冠脉综合征伴糖尿病患者介入术后心肌灌注及心肌损伤的影响[J]. 中国循证心血管医学杂志, 2012,4(4):353-356. [10]Yang YJ, Zhao JL,You SJ, et al. Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion[J]. Heart, 2006,92(8):1131-1134. [11]Tasal A, Bacaksiz A, Vatankulu MA, et al. Is postdilatation with a noncompliant balloon necessary after coronary stent deployment during primary angioplasty[J]. J Interv Cardiol, 2013,26(2):325-331. [12]伍继初, 罗参香, 欧阳泽伟. 早期应用替罗非班对老年急性冠脉综合征患者PCI术后的影响[J]. 中国现代医药杂志, 2014, 16(8):37-39.
2017, Vol. 34 
